4.6 Article

CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 84, Issue 4, Pages 913-920

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.10.094

Keywords

atherosclerosis; biomarkers; cardiovascular disease; endothelial cell; inflammation; psoriasis; vascular health

Categories

Funding

  1. National Institutes of Health (NIH, Bethesda, MD) training grant [T32HL098129]
  2. NIH Clinical and Translational Science Awards at New York University Awards (New York, NY) [UL1TR001445, KL2TR001446, TL1TR001447]
  3. American Heart Association Career Development Grant (Dallas, TX) [18CDA34110203AHA, 18CDA34080540]
  4. Dermatology Foundation
  5. American Society of Hematology grant [18-A0-00-1001884]
  6. NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR074500]
  7. Riley Family Foundation
  8. Beatriz Snyder Foundation
  9. Rheumatology Research Foundation
  10. National Psoriasis Foundation Grant
  11. NIH [R01HL139909, R01HL114978, R35HL144993]

Ask authors/readers for more resources

The study demonstrated that CCL20 expression is closely associated with vascular endothelial inflammation in psoriasis patients and may serve as a potential biomarker of impaired vascular health. CCL20, IL-6, and IL-17A were the top three circulating proinflammatory cytokines in psoriasis.
Background: Psoriasis is associated with increased cardiovascular risk that is not captured by traditional proinflammatory biomarkers. Objective: To investigate the relationship between Psoriasis Area and Severity Index, circulating proinflammatory biomarkers, and vascular health in psoriasis. Methods: In patients with psoriasis and in age and sex-matched controls, 273 proteins were analyzed with the Proseek Multiplex Cardiovascular disease reagents kit and Inflammatory reagents kit (Olink Bioscience), whereas vascular endothelial inflammation and health were measured via direct transcriptomic analysis of brachial vein endothelial cells. Results: In psoriasis, chemokine ligand 20 (CCL20), interleukin (IL) 6, and IL-17A were the top 3 circulating proinflammatory cytokines. Vascular endothelial inflammation correlated with CCL20 (r = 0.55; P < .001) and less so with IL-6 (r = 0.36; P = .04) and IL-17A (r = 0.29; P = .12). After adjustment for potential confounders, the association between CCL20 and vascular endothelial inflammation remained significant (beta = 1.71; P = .02). In nested models, CCL20 added value (chi(2) = 79.22; P < .001) to a model already incorporating the Psoriasis Area and Severity Index, Framingham risk, high-sensitivity C-reactive protein, Il-17A, and IL-6 (chi(2) = 48.18; P < .001) in predicting vascular endothelial inflammation. Limitations: Our study was observational and did not allow for causal inference in the relationship between CCL20 and cardiovascular risk. Conclusion: We demonstrate that CCL20 expression has a strong association with vascular endothelial inflammation, reflects systemic inflammation, and may serve as a potential biomarker of impaired vascular health in psoriasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available